Can a new infusion drug shrink Hard-to-Treat tumors?
NCT ID NCT07763652
First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time
Summary
This early-stage trial is testing an investigational drug called BL-ARC002 in people with advanced gastrointestinal or other solid tumors that have spread. The main goals are to find a safe dose and to see if the drug shows any signs of shrinking tumors. Participants receive the drug by intravenous infusion over a six-week cycle, and the study will monitor side effects and how the drug behaves in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BL-ARC002 (an investigational drug given by intravenous infusion)
- What this could lead to
- If successful, this could lead to a new treatment option for advanced solid tumors, potentially slowing tumor growth or shrinking tumors.
- What could go wrong
- This is an early-phase trial with a small number of participants, so the drug may not be effective or may cause significant side effects. The results will not be known until the trial is complete.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a new drug combo revive Immunotherapy's power against resistant tumors?